Nearly 900,000 girls aged between nine and 14 years in Papua New Guinea are expected to benefit from a new HPV vaccination programme backed by K4.2 million in Australian funding.
The initiative is designed to reduce the country's cervical cancer burden, with health estimates indicating that about 1,053 new cases are recorded each year, making it the second most common cancer in PNG.
Australia's contribution comes as the country marks World Cervical Cancer Elimination Day, with the partnership focusing on prevention through vaccination and improved access to health services for young girls.
| PNG Targets 900,000 Girls in K4.2 Million Australian HPV Vaccine Support/Photo supplied |
The funding will assist with the introduction and distribution of the human papillomavirus vaccine, alongside preparations for a nationwide immunisation campaign.
Healthcare personnel will also receive training and operational support to carry out the programme, including community outreach activities aimed at reaching girls who are not attending school and those in isolated parts of the country.
Australian High Commissioner Jamie Isbister said the funding reflected Australia's commitment to supporting PNG's efforts to protect young women from cervical cancer.
He said Australia was proud to assist with the country's first HPV vaccine rollout, describing the vaccine as an important development in preventing the disease.
“This game-changing vaccine, developed by Australian researchers, will provide a lifetime of protection against cervical cancer for young girls across the country,” H.E Jamie Isbister said.
Australia is expected to coordinate its support with the PNG Government and key development partners, including UNICEF, WHO and Gavi, to strengthen vaccination services and advance the country's ambition of a future without cervical cancer.